Evaluation of a commercially available rapid urinary porphobilinogen test by Vogeser, Michael & Stauch, Thomas
Clin Chem Lab Med 2011;49(9):1491–1494  2011 by Walter de Gruyter • Berlin • Boston. DOI 10.1515/CCLM.2011.605
2011/036
Article in press - uncorrected proof
Short Communication
Evaluation of a commercially available rapid urinary
porphobilinogen test
Michael Vogeser1,* and Thomas Stauch2
1 Institute of Clinical Chemistry, University of Munich,
Munich, Germany
2 MVZ Labor Prof. Seelig, Karlsruhe, Germany
Abstract
Background: Demonstration of substantially increased uri-
nary excretion of porphobilinogen is the cornerstone of diag-
nosing acute porphyria crisis. Because porphobilinogen
testing is not implemented on clinical chemistry analysers,
respective analyses are available in rather few clinical labo-
ratories. The aim of this study was to critically describe and
to evaluate a semi-quantitative rapid test for urinary porpho-
bilinogen determination which is commercially available and
recommended by the American Porphyria Foundation.
Methods: Urinary samples from patients with acute inter-
mittent porphyria and control samples were analysed and the
semi-quantitative results were compared with the results
obtained by a manual quantitative spectrophotometric method.
Results: In all 32 samples studied, acceptable agreement
between the results of the rapid test and the quantitative test
was observed. Handling of the test was found to be
convenient.
Conclusions: The assay was found to be reliable and has
the potential to increase the availability of porphobilinogen
testing in the field.
Keywords: acute intermittent porphyria; porphobilinogen;
rapid test.
Extremely high concentrations of porphobilinogen (PBG;
Figure 1A) are pathognomonic for crises of acute porphyrias
(i.e., of acute intermittent porphyria, variegate porphyria,
hereditary coproporphyria) (1). The clinical symptoms of this
rare disease condition are polymorphic, but very intensive
abdominal pain (typically requiring opiates) is found in most
cases. Profound hyponatremia, and autonomous, peripheral
and central neuropathy are also typical features. Whereas
central neuropathy can be associated with psychiatric symp-
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toms, peripheral neuropathy can progress to tetraplegia. Once
diagnosed, porphyria crisis can be terminated in most cases
by administration of haem arginate, withdrawal of porphy-
rinogenic drugs and control of triggers, such as hypoglycae-
mia, alcohol or infections. Although indeed very rare, acute
porphyria crisis has to be excluded not infrequently in
patients with etiological obscure abdominal pain or neuro-
pathy of unknown origin. Thus, it is evident that early and
reliable biochemical diagnosis or exclusion of porphyria by
urinary PBG quantification is of crucial importance to avoid
unnecessary interventions (such as laparotomy), but also to
initiate efficient therapy using haem arginate in porphyria
crisis. Thus, urinary PBG measurement should be available
for all emergency departments.
Automated tests for urinary PBG implemented on routine
clinical chemistry analysers are not available. The analyte
can be quantified using two commercially available photo-
metric tests which are handled manually. These tests require
a spectrophotometer and substantial practical expertise. The
tests are time-consuming, in particular as reagents have to
be freshly prepared for analysis. Consequently, the imple-
mentation of these tests (available from Bio-Rad Laborato-
ries and from Recipe, Munich, Germany) is a substantial
challenge in the setting of a ‘‘24/7’’ short turnaround time
(STAT) clinical laboratory.
Previously, a semi-quantitative colour test for urinary PBG
has become available (Thermo Scientific, Waltham, MA,
USA; www.thermofisher.com). This test does not require
special laboratory equipment because results are classified
by visual inspection of a colour reaction; reagents have a
long shelf life and the manual workload of testing is limited.
Because during acute porphyria attacks no borderline results
of urinary PBG with respect to the upper limit of the refer-
ence range (-2.3 mg/L; www.porphyria-europe.com) are
found but concentrations are typically more than 10-fold
increased, such a semi-quantitative test can be useful for
making the diagnosis of acute porphyria. Indeed, this test is
recommended by the American Porphyria Foundation (www.
porphyriafoundation.com). However, so far no data have
been reported with regard to the analytical performance of
this test. We therefore decided to perform a bicentric inves-
tigation of this test regarding practicability and analytical
reliability.
The Thermo PBG test kit is based on the Watson-Schwartz
test or Hoesch test, respectively. In this test, PBG condenses
with 4-dimethylamino-benzaldehyde (DMAB) in acid solu-
tion to form a magenta coloured product (Figure 1B). To
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Figure 1 (A) Molecular structure of porphobilinogen. (B) Reaction of DMAB and porphobilinogen forming a magenta coloured complex.
Figure 2 Components of the Thermo PBG test kit. 1, Elution re-
agent (1 M acetic acid); 2, 4-dimethylamino-benzaldehyde
(DMAB), working solution; 3, reaction tube; 4, resin-filled syringe;
5, filter; 6, colour chart.
obtain adequate specificity of this procedure, interfering
compounds (such as urobilinogen) have to be removed from
the urine sample before the reaction is initiated. The Thermo
PBG test utilises an anion exchange resin which binds the
analyte; interfering compounds are removed during a wash-
ing step while PBG is finally eluted into the acidified DMAB
solution. Colour development is compared with a three-cat-
egory colour chart, referring to concentrations of 6 mg/L,
12 mg/L, and 23 mg/L.
The DMAB solution has to be activated by mixing two
components of the kit (DMAB powder and 6.1 M HCl); once
prepared, this solution is claimed to be stable for at least
12 months at room temperature. The pH of the urine sample
has to be checked before analyses, and has to be corrected
to pH 6–8 if necessary with dilute ammonia solution
(approximately 8%; not included in the test kit). Essentially
the analytical procedure includes: drawing up 1 mL of urine
into the resin-containing syringe; expelling the urine after
some seconds of mixing (which is facilitated by an air bubble
drawn into the syringe); drawing up of distilled water and
expelling the water after mixing; drawing up 1 mL of a
ready-to-use elution reagent (1 M acetic acid); expelling the
solution into a transparent reaction tube containing 1 mL of
DMAB reagent. After 3 min, the colour of the solution
observed against a white background is compared to a colour
chart showing the typical colours for three distinct PBG con-
centrations (6 mg/L, 12 mg/L, 23 mg/L). According to the
test instruction the results are given as ‘‘ND’’ (PBG -6
mg/L), ‘‘q’’ (PBG 6–12 mg/L), ‘‘qq’’ (PBG 12–23
mg/L), or ‘‘qqq’’ (PBG)23 mg/L). The kit contains
extraction syringes with 5 mm pre-filter devices, DMAB
powder, 6.1 M HCl for dissolving, elution reagent (1 M ace-
tic acid), reaction vials and a colour chart for 20
determinations
(Figure 2). The manufacturer recommends confirming posi-
tive tests using quantitative analysis in an experienced
laboratory.
The test kit was evaluated in two laboratories:
Site 1 (Karlsruhe): five leftover samples (stored at –258C
for -2 weeks) of patients with acute porphyria, and 12 sam-
ples from healthy volunteers were analysed with the Thermo
rapid test and a quantitative, spectrophotometric PBG test
based on the procedure of Mauzerall and Granick (2) (Rec-
ipe, Mu¨nchen, Germany). All samples from patients were
identified as pathological and all samples from healthy vol-
unteers gave negative readings with the Thermo test. The
patients’ results were as follows (quantitative result, mg/L,
vs. concentration specified for the field of the colour standard
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Table 1 Raw data of a method comparison study between a semi-quantitative rapid test for urinary porphobilinogen measurement (Thermo
Scientific) and a quantitative spectrophotometric test (Bio-Rad).
 Sample description Thermo test Bio-Rad assay
(semi-quantitative) (quantitative)
PBG mg/La PBG mg/L
1 Quality control sample ‘‘RECIPE’’ 12 13.4
(lyophilisate reconstituted with water)
Target: PBG 14.9 mg/L
2 Healthy volunteer’s urine Undetectable -0.5
3 Quality control sample ‘‘RECIPE’’ w1x 6 6.8
diluted 1q1 with volunteer’s urine w2x
Expected: PBG 7.5 mg/L
4 Porphyria patient’s urine 23 22.0
5 Patient’s urine w4x diluted 12 11.6
1q1 with volunteer’s urine w2x
Expected: PBG 11.0 mg/L
aIdentical results of several determinations. Conversion of units for PBG: wmmol/Lx=0.226™wmg/Lx; wmg/Lx=4.420™wmmol/Lx. Linear
regression between ‘‘best matching chart field’’ concentration and quantitative test result: rs0.99; Bio-RadsThermo=0.88–1.9 mg/L.
from the Thermo test with the closest agreement to the
patient’s sample): 45.6 vs. 23; 10.1 vs. 12; 16.8 vs. 12; 4.2
vs. 12; and 43.3 vs. 23.
Site 2 (Munich): a residual native urinary sample from a
patient suffering from an acute crisis of porphyria as well as
urine from a healthy volunteer were used. An aliquot of the
patient’s urine was diluted 1:2 with the volunteer’s urine.
Furthermore, a commercially available quality control sam-
ple was investigated (Recipe), native after reconstitution as
well as in dilution 1:2 with the volunteer’s urine. PBG con-
centrations of the original patient’s sample, of the quality
control samples and of the blended samples were quantified
using a commercially available spectrophotometric PBG kit
(Bio-Rad Laboratories). From each of these samples, several
aliquots of 1 mL each were prepared and identified with
serial numerical labels, not disclosing the respective PBG
concentrations. The sequential number of the aliquot and the
determined PBG determination were documented. A total of
15 sample aliquots (3= quality control sample; 5= healthy
volunteer’s urine; 2= diluted quality control sample; 3=
patient’s urine; 2= patient’s diluted urine) were then analy-
sed using the Thermo semi-quantitative test on the same day
in a blinded manner by a regularly trained technician who
was not involved in the preparation of the samples. Accord-
ing to visual inspection of the solutions obtained, the results
were assigned to the colour reference field with the closest
agreement (6 mg/L, 12 mg/L, 23 mg/L). Finally, the results
were unblinded by the investigator and the listings of distri-
buted samples’ concentrations and the findings were matched.
For the 15 aliquots of all five samples agreement of quan-
titative and semi-quantitative results was found (Table 1).
Several fold analysis of individual samples gave identical
semi-quantitative read-outs, demonstrating unit-to-unit repro-
ducibility of results.
The Thermo test kit used for validation was activated
11 months prior to the study by making up the DMAB work-
ing solution.
We conclude from our data and our handling experiences
that the Thermo PBG test kit is applicable in the setting of
a STAT clinical laboratory and that reliable screening results
can be obtained. Owing to the semi-quantitative nature of
the assay, standard clinical chemistry method validation pro-
tocols were not applicable; and because acute intermittent
porphyria is a very rare disease, the availability of native
positive samples was limited. However, using several origi-
nal patients’ samples (native and in dilution) we were able
to demonstrate that no misleading results were obtained in
our concise evaluation program.
In our laboratories, the Thermo PBG test is applied in case
of any diagnostic request outside the routine working hours,
whereas a quantitative test is applied whenever possible. The
availability of a quantitative test in addition to a semi-quan-
titative screening test is, in particular, essential for the fol-
low-up of diagnosed patients undergoing therapy.
The Thermo PBG test kit users’ instructions recommend
quality control by analyzing ‘‘known positive urine’’. Such
material is rarely available for most laboratories. Thus, the
kit could be improved by providing PBG pure compound
aliquoted quantitatively in reaction vials which could be dis-
solved with water before used as a (positive) quality control.
Furthermore, the practicability of the kit would be improved
by inclusion of dipsticks for urinary pH measurement and of
ammonia solution for pH adjustment if necessary in individ-
ual samples.
Rapid testing for urinary PBG is not at all new. The test
described by Schwartz and Watson with visual inspection of
a colour change is still used in a number of laboratories as
well as a modified procedure, the ‘‘Hoesch test’’ (3). How-
ever, these tests are inconvenient because solutions are not
stable and have to be freshly prepared for analysis. The reli-
ability of these screening tests has been reported to be poor
(4). They are known to be very unspecific owing to side
reaction with many interfering substances, such as urobili-
nogen or aminoacetone, leading to false-positives, or high
urea concentrations potentially leading to false-negatives.
Compared to traditional in-house screening tests, the Ther-
mo PBG assay has the essential advantage of increased spec-
ificity owing to a sample extraction step using a resin. This
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screening test approach has been described previously (5, 6).
However, individually configured, not commercially availa-
ble tests are a challenge to be implemented in STAT labo-
ratories. A semi-quantitative rapid PBG test kit using
pretreatment with ion-exchange resin and a colour reaction
was described in 1998 (7); however, this test did not find
widespread use and is to our knowledge not available any
more.
When compared to quantitative PBG test kits, it is an
essential advantage of the Thermo rapid test that no labora-
tory instruments are required and that solutions are ready-to-
use with a shelf life of 1 year after activation. The rapid test
for urinary PBG evaluated here indeed offers a very con-
venient handling; this might enable a more widespread avail-
ability of PBG testing for emergency units and could finally
improve patient care.
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